Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S (NOVO B)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
01/10/2018 01/11/2018 01/12/2018 01/15/2018 01/16/2018 Date
339.4(c) 336(c) 336.55(c) 334.75(c) 339 Last
2 636 696 2 150 852 1 933 495 1 886 460 2 470 032 Volume
-1.14% -1.00% +0.16% -0.53% +1.27% Change
More quotes
Financials ( DKK)
Sales 2017 112 B
EBIT 2017 49 247 M
Net income 2017 38 469 M
Finance 2017 18 482 M
Yield 2017 2,34%
Sales 2018 116 B
EBIT 2018 50 237 M
Net income 2018 39 963 M
Finance 2018 18 210 M
Yield 2018 2,49%
P/E ratio 2017 21,55
P/E ratio 2018 20,30
EV / Sales2017 5,69x
EV / Sales2018 5,52x
Capitalization 657 B
More Financials
Company
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes and Obesity Care; and Biopharmaceuticals segments.The Diabetes and Obesity Care segment covers products for insulin; GLP-1 and... 
Sector
Pharmaceuticals
Calendar
02/01Earnings Release
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
01/15 NOVO NORDISK A/S : - Share repurchase programme
01/12 NOVO NORDISK A/S : AS - Share repurchase programme
01/12 DIAGNOS : Announces the Management of the Flagship Nuevo Yo Program by Novo Nord..
01/10 Bond sell-off hits European shares but boost banks
01/10 NOVO NORDISK A/S : Team Novo Nordisk and Giessegi Srl Announce Partnership
01/10 NOVO NORDISK A/S : urges Ablynx board to negotiate acquisition
01/09 NOVO NORDISK A/S : Team Novo Nordisk and Giessegi Srl Announce Partnership
01/09 NOVO NORDISK A/S : Ozempic® approved in Canada for the treatment of adults with ..
01/09 Drug Firm Rejects $3.13 Billion Offer From Novo Nordisk -- WSJ
01/08 ABLYNX : dismisses EUR 2.6bn Novo Nordisk offer
More news
Sector news : Pharmaceuticals - NEC
01/15 Drugmaker Dermapharm gears up for likely first German IPO of 2018
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
01/12 ASTRAZENECA : Receives FDA Approval for Breast Cancer Treatment
01/12 WPP Buys London-based Mash Strategy
More sector news : Pharmaceuticals - NEC
Latest Tweets
01/13Novo Nordisk's $3.1B Ablynx bid rejected by Belgian biotech
2
01/10Novo Nordisk’s once-weekly diabetes injection cleared in Canada: Drug Deliver..
1
01/09$NVO: Novo Nordisk A/S announced that Health Canada has approved Ozempic as a.. 
01/09Ablynx (ABLX) Surged To A New High After Rejecting Takeover Bid: Ablynx (ABLX.. 
01/08Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid  
More tweets
Qtime:77
News from SeekingAlpha
01/14 Investment Ideas In Quality Stocks
01/10 YOUR DAILY PHARMA SCOOP : Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides..
01/09 10 Nordic Companies Worth Knowing About
01/09 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Bid, Celgene Acquires Impact Biomedici..
01/09 Novo's Ozempic OK'd in Canada for type 2 diabetes
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 319  DKK
Spread / Average Target -4,7%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S0.61%108 273
JOHNSON & JOHNSON4.32%388 981
NOVARTIS1.80%224 968
PFIZER0.88%217 923
ROCHE HOLDING LTD.-0.28%217 905
MERCK AND COMPANY4.25%159 987